IMMvention Therapeutix, Inc.
PrivateLast Round
Early Funding
Jan 10, 2023
Total Funding Raised
$6.65M
Company Overview
IMMvention Therapeutix, Inc. operates in Healthcare & Life Sciences and is based in Durham, North Carolina. Its latest recorded funding round was an Early Funding round in January 2023.
IMMvention Therapeutix, Inc. is a biotechnology company that discovers and develops oral small-molecule therapeutics for diseases with high unmet medical needs, including sickle cell disease, cardiometabolic, renal, and neuroinflammatory conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IMMvention Therapeutix, Inc. Comparables
Compare IMMvention Therapeutix, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NodThera | 85% | |
| Olatec Therapeutics | 84% | |
| Eli Lilly and Company | 76% |
For institutional investors. Book with your work email.
IMMvention Therapeutix, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jan 10, 2023 | ||||
| Series A | Dec 1, 2020 | ||||
| Debt | Aug 21, 2020 | ||||
| Debt | Oct 30, 2019 | ||||
| Grant | Jun 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
IMMvention Therapeutix, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hatteras Venture Partners | Early Funding, Series A |
| Osage University Partners | Early Funding, Series A |
| Alexandria Venture Investments | Early Funding, Series A |
| North Carolina Biotechnology Center | Debt, Early Funding |
| National Institutes of Health (NIH) | Grant |
| Delin Ventures | Early Funding, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 3, 2026
Grew 27% QoQ, from 11 to 14 employees.
- Apr 20, 2026
Monthly visitors grew 727% MoM, reaching 1.7K.
For institutional investors. Book with your work email.
IMMvention Therapeutix, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about IMMvention Therapeutix, Inc.'s valuation, stock price, and market status.
Is IMMvention Therapeutix, Inc. a public or private company?
IMMvention Therapeutix, Inc. is a private company.
What is the current stock price of IMMvention Therapeutix, Inc.?
IMMvention Therapeutix, Inc. is a private company, so its shares have no public market price. Caplight tracks IMMvention Therapeutix, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is IMMvention Therapeutix, Inc. worth (valuation)?
Valuation information for IMMvention Therapeutix, Inc. is not publicly available.
Can I buy IMMvention Therapeutix, Inc. stock?
IMMvention Therapeutix, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was IMMvention Therapeutix, Inc.'s last funding round?
IMMvention Therapeutix, Inc.'s most recent funding round was Early Funding on January 10, 2023.
Who are the main investors in IMMvention Therapeutix, Inc.?
Key investors in IMMvention Therapeutix, Inc. include North Carolina Biotechnology Center, National Institutes of Health (NIH).
Will IMMvention Therapeutix, Inc. IPO soon?
No public IPO plans have been announced for IMMvention Therapeutix, Inc..
How can I track IMMvention Therapeutix, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in IMMvention Therapeutix, Inc.'s shares on secondary markets.